Latest Market Launch News

Finbar Group (ASX:FRI) delivered its strongest annual profit since FY2015, with net profit rising 40.9% to $20.3 million despite lower revenue. Record pre-sales, reduced debt and a $1.95 billion development pipeline give the Perth apartment developer a substantial FY27 workload.

Finbar has moved its Romeo apartment project in Applecross into construction after securing 103 sales worth A$121.1 million. Recent activity has accelerated, with investors accounting for about half of the 18 lots sold since 1 August.

CurveBeam AI has secured over A$600,000 through its Share Purchase Plan, bolstering funds alongside a recent A$5 million placement. The capital will fuel the China launch and product development for its HiRise™ CT scanner.

Orbital Corporation has broadened its customer base and product lineup, positioning itself to capture growth in defence and commercial UAV markets with $3.2 million in expected sales for Q1 FY2027.

Finbar has completed settlement on a prime South Perth development site with an estimated end value of $402 million, adding scale and strategic depth to its $1.95 billion five-year pipeline.

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.

The Koala Company posted a $24.6 million profit for FY26 on $332.3 million revenue, surpassing IPO forecasts with strong international growth and margin gains.

Finbar Group delivered its strongest profit since FY15 with a 41% rise in NPAT to $20.3 million despite a 28% revenue decline, underpinned by record pre-sales and a robust development pipeline exceeding $1.8 billion.

ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.

4DMedical has secured a pivotal three-year contract with SimonMed Imaging to deploy its CT:VQ™ lung imaging technology across over 170 US outpatient centres, while FY26 revenue rose 23% to $7.2 million on record scan volumes and global expansion.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

Cleo Diagnostics has entered the critical Analytical Validation phase for its ovarian cancer blood test, progressing toward an FDA 510(k) submission targeted for the first half of 2027. The company also secured a U.S. reimbursement pathway to support early market entry post-clearance, backed by a cash balance of A$6.2 million.